AROMATASE INHIBITORS: SKELETAL EFFECTS AND THE ROLE OF CYP19 GENE POLYMORPHISMS

芳香酶抑制剂：骨骼效应和 CYP19 基因多态性的作用

• 批准号: 7267973
• 负责人: REINA C VILLAREAL
• 金额: $ 16.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7267973
• 关键词: Acute; Address; Adjuvant Therapy; Adrenal Glands; Adverse effects; Age-Related Bone Loss; Alleles; Anabolism; Androgens; Androstenedione; Aromatase; Aromatase Inhibition; Aromatase Inhibitors; Bone Density; Breast Cancer Prevention; CYP19A1 gene; Chronic; Class; Coagulation Process; Code; Conflict (Psychology); Data; Development; Diagnosis; Disease; Disease-Free Survival; Endometrial Carcinoma; Enzyme Inhibitor Drugs; Enzyme Inhibitors; Enzymes; Estradiol; Estrogen receptor negative; Estrogen receptor positive; Estrogens; Estrone; Ethnic group; Exemestane; Exhibits; Failure; Fracture; Generations; Genes; Genetic Polymorphism; Genetic Variation; Genotype; Goals; Hand; High Prevalence; Incidence; Lead; Letrozole; Longitudinal Studies; Marketing; Measurement; Menopause; Neck; Normal tissue morphology; Numbers; Osteoporosis; Ovarian; Ovariectomy; Pathway interactions; Patients; Pharmaceutical Preparations; Pilot Projects; Postmenopause; Predisposition; Production; Rate; Rattus; Reporting; Research; Research Personnel; Risk; Role; Route; Serum; Skeletal system; Source; Staging; System; Tamoxifen; Testing; Thromboembolism; Time; Total Estrogen Blockade; Uterus; Variant; Woman; anastrozole; base; bone health; bone loss; bone metabolism; bone turnover; clinically significant; design; enzyme activity; experience; follow-up; hormone therapy; improved; malignant breast neoplasm; prevent; programs; response; sex; trend

DESCRIPTION (provided by applicant): The use of tamoxifen as the first line agent for endocrine therapy of estrogen receptor positive (ER+) breast cancer has recently been challenged by a newer class drugs, the aromatase inhibitors, which are found to have superior efficacy over tamoxifen with better side-effect profile. On the other hand, because of it's mechanism of action, bone loss is understandably a concern among these women. Reports of an increased incidence of fractures in women on aromatase inhibitors, a few were significant and some not, came from studies that were not designed to investigate the skeletal effects of the drug. No data on bone mineral density (BMD) were available from these studies, thus, bone loss was not adequately addressed. Previous studies have identified certain polymorhisms of the CYP19 gene (the gene that codes for the aromatase enzyme) to be associated with differences in enzymatic activity and BMD. Whether these polymorphisms influence the skeletal response to aromatase inhibition remains undetermined. We hypothesize that the use of aromatase inhibitors is associated with significant bone loss, and the degree of bone loss will be determined by polymorphisms of the CYP19 gene. To test this hypothesis we propose to do a one-year longitudinal study of postmenopausal women from different ethnic groups who will be initiated on aromatase inhibitors for breast cancer. Women with breast cancer but will not be put on aromatase inhibitors will serve as controls. We will obtain BMD measurements and markers bone turnover at baseline and on follow-up. We will also genotype these women for CYP19 gene polymorphisms associated with differences BMD. We will compare the rates of bone loss in women on aromatase inhibitors versus those not taking the drug, and also among the different variants of the different polymorphisms examined. We anticipate that significant bone loss is associated with aromatase inhibitor therapy and but certain variants of the CYP19 gene are especially more sensitive to inhibition, thus, will be experiencing more bone loss than others. The data generated from this proposed study will be used to develop a full-scale proposal with the goal of establishing the appropriate approach to maintaining bone health in women given aromatase inhibitors. As more patients are surviving breast cancer, more will be expected to experience osteoporotic complications from endocrine therapies intended to improve survival, thus, this issue needs to be addressed.

描述（由申请人提供）：他莫昔芬作为雌激素受体阳性（ER+）乳腺癌内分泌治疗的一线药物的使用最近受到了新型药物芳香酶抑制剂的挑战，该药物被发现比其他药物具有更好的疗效。他莫昔芬具有更好的副作用。另一方面，由于其作用机制，骨质流失成为这些女性关注的问题是可以理解的。关于服用芳香酶抑制剂的女性骨折发生率增加的报告，有些是显着的，有些则不是，这些报告来自并非旨在调查该药物对骨骼影响的研究。这些研究没有提供有关骨矿物质密度（BMD）的数据，因此骨丢失问题没有得到充分解决。先前的研究已经发现 CYP19 基因（编码芳香酶的基因）的某些多态性与酶活性和 BMD 的差异有关。这些多态性是否影响骨骼对芳香酶抑制的反应尚未确定。我们假设芳香酶抑制剂的使用与显着的骨质流失有关，而骨质流失的程度将由 CYP19 基因的多态性决定。为了检验这一假设，我们建议对来自不同种族的绝经后妇女进行为期一年的纵向研究，这些妇女将开始使用芳香酶抑制剂治疗乳腺癌。患有乳腺癌但未服用芳香酶抑制剂的女性将作为对照。我们将在基线和随访时获得 BMD 测量值和骨转换标志物。我们还将对这些女性进行与 BMD 差异相关的 CYP19 基因多态性基因分型。我们将比较服用芳香酶抑制剂的女性与未服用该药物的女性的骨质流失率，以及所检查的不同多态性的不同变体之间的骨质流失率。我们预计，显着的骨质流失与芳香酶抑制剂治疗有关，但 CYP19 基因的某些变体对抑制尤其更敏感，因此，会比其他变体经历更多的骨质流失。这项拟议研究产生的数据将用于制定一项全面的提案，目标是建立适当的方法来维持服用芳香酶抑制剂的女性的骨骼健康。随着越来越多的乳腺癌患者存活下来，预计会有更多的患者因旨在提高生存率的内分泌治疗而出现骨质疏松并发症，因此，这个问题需要解决。

项目成果

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

CYP19A1 基因 Val80 (rs700518) 的遗传多态性与使用芳香酶抑制剂治疗 ER ( ) 乳腺癌的女性身体成分变化相关。

• 发表时间: 2015-08
• 作者: Napoli, Nicola;Rastelli, Antonella;Ma, Cynthia;Colleluori, Georgia;Vattikuti, Swapna;Armamento
• 通讯作者: Armamento

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.

CYP19A1 基因 Val80 (rs700518) 的遗传多态性与芳香酶抑制剂相关的 ER 乳腺癌女性骨质流失相关。

• 发表时间: 2013-08
• 影响因子: 4.1
• 作者: Napoli, Nicola;Rastelli, Antonella;Ma, Cynthia;Yarramaneni, Jayasree;Vattikutti, Swapna;Moskowitz, Gerard;Giri, Tusar;Mueller, Cheryl;Kulkarny, Vibhati;Qualls, Clifford;Ellis, Matthew;Armamento
• 通讯作者: Armamento